HTA Quarterly Spring 2026

In this edition, we discuss the risks of relying on immature data for survival projections in oncology and the importance of selecting robust models to guide HTA decisions. We also explore key challenges and developments in HTA within the UK and Germany, including the impact of limited clinical evidence on NICE appraisals, with strategies to improve submission outcomes, and recent updates to Germany’s AMNOG dossier requirements, highlighting the evolution to trend-based estimates to better align benefit assessments with statutory health insurance patient populations.